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Vedolizumab is an anti-a4b7 monoclonal antibody that is licensed for the treatment of 
moderate to severe Crohn’s disease and ulcerative colitis.
Aims
To establish the real-world efficacy and safety of vedolizumab in the treatment of 
inflammatory bowel disease.
Methods
Retrospective study involving six NHS health boards in Scotland between June 2015 and 
November 2017. Inclusion criteria included a diagnosis ulcerative colitis or Crohn’s disease 
with objective evidence of active inflammation at baseline (HBI≥5 / Partial Mayo ≥2 plus 
CRP >5 g/L or faecal calprotectin ≥250 µg/g or inflammation on endoscopy / MRI) and at 
least one clinical follow up by 12 months. Kaplan-Meier survival analysis was used to 
establish 12-month cumulative rates of clinical remission (HBI <5 or Partial Mayo <2), 
mucosal healing (absence of ulceration/erosions on colonoscopy/MRI or Mayo score 0) and 
deep remission (clinical remission plus mucosal healing). Rates of serious adverse events 
were described quantitatively.  
Results
Our cohort consisted of 180 patients with ulcerative colitis and 260 with Crohn’s disease. 
Combined median follow up was 52 weeks (IQR 26-52 weeks).  In ulcerative colitis, 12-
month cumulative rates of clinical remission, mucosal healing and deep remission were 
57.4%, 47.3% and 38.5% respectively. In Crohn’s disease, 12-month cumulative rates of 
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clinical remission, mucosal healing and deep remission were 58.4%, 38.9% and 28.3% 
respectively. The serious adverse event rate was 15.6 per 100 patient years of follow up.
Conclusion
Vedolizumab is a safe and effective treatment for achieving both clinical remission and 
mucosal healing in ulcerative colitis and Crohn’s disease. 
 
Keywords: Vedolizumab, real-world, Crohn’s disease, Ulcerative colitis, mucosal healing.  
Page 5 of 39
https://mc.manuscriptcentral.com/ecco-jcc
































































The anti-TNF monoclonal antibodies have revolutionized the treatment of patients with 
inflammatory bowel disease (IBD). Clinical trials have clearly demonstrated their ability to 
induce and maintain clinical remission but also achieve mucosal healing in patients with 
IBD.1,2,3 However, up to 30% and 45% of patients will experience a primary loss or 
secondary loss of response respectively.4 Furthermore, the systemic immunosuppressive 
effect of anti-TNF agents is associated with significant morbidity.5 Therefore, alternative 
treatments with different mechanisms of actions are required.
Vedolizumab is a human monoclonal antibody that targets a4b7 integrin and blocks 
lymphocyte trafficking to the gut via the MADCAM pathway.6 Following the phase 3 GEMINI 
trials, that demonstrated efficacy in induction and maintenance of clinical remission in both 
ulcerative colitis (UC) and Crohn’s disease (CD), vedolizumab was approved as the first gut 
selective biologic for the treatment of moderate to severe inflammatory bowel disease 
(IBD).7,8,9 In GEMINI 1 and 2, 41.8% and 39.0% of UC and CD responders were in clinical 
remission at week 52 respectively.7,8 However, because of the strict inclusion and exclusion 
criteria adopted in the seminal trials (e.g. age restrictions, exclusion of patients with stomas, 
stricturing disease or multiple small bowel resections) the populations treated are not always 
representative of those encountered in routine clinical practice.10 Therefore, establishing the 
effectiveness and safety of vedolizumab in real-world settings is essential, especially when 
considering how it should be positioned in treatment algorithms.  
To this date a number of real world studies have published data on the effectiveness and 
safety of vedolizumab.11 However, limitations of several studies include their small sample 
size, small anti-TNF naive numbers, lack of long-term follow up and confinement to specialist 
tertiary centres.11 Furthermore, with the paradigm shift of treating beyond clinical symptoms 
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to normalisation of faecal calprotectin (FC) and mucosal healing, increasing data is required 
on the ability of vedolizumab to achieve these objective end-points in the real world.12 
Therefore, in this study we aimed to assess the real-world effectiveness and safety of 
vedolizumab utilising a large multicentre Scottish cohort of patients with IBD, primarily 
looking to assess cumulative rates of clinical remission and mucosal healing by 12-months.
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This was a multi-centre retrospective cohort analysis involving thirteen hospitals within six 
NHS health-boards across Scotland (NHS Lothian [co-ordinating site], NHS Greater 
Glasgow and Clyde, NHS Lanarkshire, NHS Fife, NHS Forth Valley, NHS Highlands). Data 
were retrospectively collected at each hospital by review of electronic medical records.
2.2 Data Collection
A standardised electronic data collection pro-forma was used at all sites. Baseline 
parameters for patient phenotyping were obtained. Follow up data on clinical disease activity 
(Harvey-Bradshaw Index [HBI] / Partial Mayo score/ Physician’s global assessment [PGA]), 
faecal calprotectin (FC), endoscopy, radiology, surgery, steroid use and adverse events 
were collected where possible via review of electronic medical records. All data had been 
prospectively collected as part of routine clinical care.
2.3 Participants
Patients receiving vedolizumab for IBD between June 2015 and November 2017 were 
identified following review of prescribing, infusion suite and electronic medical records at 
each site. Inclusion criteria for our analysis were: (a) confirmed diagnosis of CD or UC 
(based on standard clinical, radiological, endoscopic and histological criteria); (b) active 
disease prior to starting vedolizumab defined by either a HBI ≥5 or Partial Mayo score ≥2 
plus CRP ≥5 mg/L and/or endoscopic / radiographic assessment and/or FC ≥250 µg/g (c) 
completion of standard induction dosing (0, 2, 6 weeks); (d) at least one clinical follow up 
(assessment of disease activity score) within 12-months of initiation of vedolizumab. 
Patients with inflammatory bowel disease unknown (IBDU) were included in the UC analysis 
unless pathology favoured CD. Patients who did not complete induction were excluded. 
Page 8 of 39
https://mc.manuscriptcentral.com/ecco-jcc































































Patients on vedolizumab but no objective evidence of active disease at baseline or receiving 
treatment for the indication of pouchitis and microscopic colitis were also excluded from the 
analysis. 
2.4 Primary and Secondary Outcomes
Our primary outcomes were the proportion of patients achieving clinical remission and 
mucosal healing. Secondary outcomes included: proportion of patients achieving deep 
remission (clinical remission plus mucosal healing); change in FC during follow up; rates of 
resectional surgery; baseline predictors of outcome; and serious adverse events. 
Achievement of mucosal healing was determined from endoscopy or radiology reports. 
Serious adverse events were defined as any event leading to disruption or discontinuation 
of therapy, hospitalisation or death.
2.5 Ulcerative Colitis Definitions
Clinical remission was defined as a Partial Mayo score <2 and complete tapering of steroids. 
Mucosal healing was assessed either by flexible sigmoidoscopy or ileo-colonoscopy and 
defined as an Endoscopic Mayo score of 0 with complete tapering of steroids. Where a score 
was not documented it was determined by review of endoscopy reports / photos. At least 
one assessment of mucosal healing by flexible sigmoidoscopy or ileo-colonoscopy was 
available in 101/180 UC patients (56.1%).
2.6 Crohn’s Disease Definitions
Clinical remission was defined as a HBI <5 off steroids (PGA used in patients with stoma). 
Mucosal healing was defined as the absence of mucosal ulceration / erosions on ileo-
colonoscopy and off steroids. In patients where ileo-colonoscopy was not possible mucosal 
healing was assessed by MRI (defined according to local site radiologist) or capsule 
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endoscopy (defined according to local site physician) where available. We were unable to 
apply any validated MRI scoring indices, therefore a sensitivity analysis was performed 
excluding individuals who had a mucosal assessment based on radiology alone. At least 
one assessment of mucosal healing was available in 140/260 CD patients (53.8%), 
performed via; ileo-colonoscopy in 114 (81.4%); MRI in 25 (17.9%) because of stricturing 
disease (n=21) or proximal small bowel disease (n=4); and capsule endoscopy in 1 (0.7%) 
because of proximal small bowel disease.
2.7 Statistical Analysis 
SPSS Version 24 (IBM Inc., Chicago, IL, USA) and Prism Version 7.0 (Graphpad Software, 
San Diego, CA, USA) were used for statistical analyses and generation of graphs. 
Descriptive statistics are presented as medians with interquartile range (IQR) for continuous 
variables and frequencies with percentages for categorical variables. For comparison of 
non-parametric continuous variables, the Mann-Whitney U or Kruskall-Wallis test was used 
where appropriate. For comparison of categorical variables, the Chi-squared test was used. 
Primary and secondary outcomes were assessed using Kaplan-Meier survival analysis and 
comparisons made using the log-rank test. Patients were censored at failure, last follow up 
(if less than 365 days) or at 365 days follow up. To try and account for some of the possible 
bias introduced from retrospective observational data with varying follow up, we performed 
a non-responder imputation (NRI) analysis to obtain a conservative estimate of outcomes at 
12 months. Cox proportional hazard regression analyses were carried out to identify 
possible baseline predictors of clinical remission, mucosal healing and deep remission. 
Variables for analysis were chosen a-priori and are listed in Supplementary table 1. 
Variables from the univariable analysis with a p-value <0.20 were fitted and a stepwise 
backward selection approach was adopted to identify significant predictors. A p-value <0.05 
was considered significant for all statistical tests.    
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This study was considered a retrospective audit by the local ethics committee as all data 
was collected as part of routine clinical care; hence no formal ethical approval was 
necessary. Caldicott guardian approval (NHS Lothian) was granted for data collection, 
storage and submission for publication (Application ID: 1845). 
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A total of 481 patients receiving vedolizumab were identified. Of these, 180 UC and 260 CD 
patients fulfilled our inclusion criteria for analysis (Figure 1, Table 1). The median follow up 
(time from initiation to last infusion or discontinuation) was 51 weeks (IQR 26-52 weeks) for 
CD and 52 weeks (IQR 26-52 weeks) for UC. Patient demographics and disease 
characteristics are shown in Table 1. Amongst the CD patients, 230 (88.5%) had been 
previously exposed to anti-TNF with 62.7% receiving vedolizumab as either 3rd or 4th line 
biologic. Amongst the UC patients, 111 (61.7%) had been previously exposed to anti-TNF. 
3.2 Ulcerative colitis outcomes 
The cumulative rates of clinical remission (Partial Mayo score <2) were 20.0%, 43.3% and 
57.4% at 3, 6 and 12 months respectively. The median time to first endoscopic assessment 
was 13 weeks (IQR 13-51 weeks). Cumulative rates of mucosal healing (Endoscopic Mayo 
score of 0) were 17.9% and 47.3% after 6 and 12 months of treatment respectively. In those 
achieving outcome, median time to clinical remission and mucosal healing was 14 weeks 
(IQR 13-26 weeks) and 26 weeks (IQR 22-51 weeks) respectively. The cumulative rates of 
deep remission (mucosal healing plus clinical remission) at 6 and 12 months were 14.3% 
and 38.5% respectively. Utilising a NRI analysis at 12 months; clinical remission, mucosal 
healing and deep remission was achieved in 19.4% (n=35/180), 15.8% (n=16/101) and 
10.9% (n=11/101) of patients respectively. Cumulative clinical remission rates were 
significantly higher in patients without endoscopic follow up compared to those with (74.6% 
vs 43.6% at 12 months, log-rank p<0.01) (Supplementary Figure 1). A significant drop in 
faecal calprotectin levels was observed after 3, 6 and 12 months of treatment compared to 
baseline (Figure 2).
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Cumulative rates of colectomy were 6.0% and 12.4% after 6 and 12 months of vedolizumab 
treatment. Amongst these patients, n=7 had received IV steroids for severe disease (n=2/7 
also started on concomitant cyclosporine) and underwent colectomy within 4 months of 
starting vedolizumab due to non-response. 
3.3 Predictors of treatment outcomes in ulcerative colitis
Multivariable Cox regression analysis identified receiving vedolizumab as first line treatment 
as the only independent predictor of clinical remission (HR 1.9, 95% CI 1.24-2.91, p<0.01), 
mucosal healing (HR 2.32, 95% CI 1.11-4.89, p=0.03) and deep remission (HR 3.78, 95% 
CI 1.55-9.22, p<0.01) (Table 2). Stratifying patients by previous TNF exposure revealed 
significantly higher cumulative rates of clinical remission (71.4% vs 48.0% at 12 months, 
log-rank p<0.01), mucosal healing (61.6% vs 34.3% at 12 months, log-rank p=0.03) and 
deep remission (58.4% vs 20.0% at 12 months, log-rank p<0.01) in patients who were anti-
TNF naïve (Table 2, Figure 3). No significant difference was observed in cumulative rates 
of colectomy between anti-TNF naïve and exposed patients (7.2% vs 15.5%, p=0.15) 
(Figure 2). Comparison of baseline disease activity measures showed no difference in 
median partial Mayo scores (6 vs 6, p=0.33) (partial Mayo scores available in n=120) or 
median CRP levels (4.0 vs 5.0 mg/L, p=0.11) (CRP available in n=164) between anti-TNF 
naïve and exposed patients. However, anti-TNF patients had significantly lower median FC 
levels at baseline (745 vs 1050 µg/g) (FC available in n=116) but higher rates of concomitant 
steroid use (62.3% vs 43.2%, p=0.01) compared to those who were anti-TNF exposed.
3.3 Crohn’s disease outcomes
Cumulative rates of clinical remission were 21.9%, 39.9% and 58.4% after 3, 6 and 12 
months of vedolizumab treatment respectively. The median time to first mucosal 
assessment was 28 weeks (IQR 14-48 weeks). Cumulative rates of mucosal healing were 
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10.1% and 38.9% after 6 and 12 months of treatment respectively. In those achieving 
remission, median time to clinical remission and mucosal healing was 14 weeks (IQR 12-26 
weeks) and 39 weeks (IQR 21-50 weeks), respectively.  
Analysis of mucosal healing, including only patients with endoscopic follow up (n=114), 
revealed cumulative rates of 12.2% and 42.6% at 6 and 12 months respectively. 
Furthermore, cumulative rates of deep remission at 6 and 12 months were 7.4% and 28.3% 
respectively. Utilising a NRI analysis at 12 months; clinical remission, mucosal healing and 
deep remission was achieved in 16.2% (n=42/260), 9.3% (n=13/140) and 7.1% (n=10/140) 
of patients respectively. Cumulative clinical remission rates were similar in patients without 
follow up for mucosal healing compared to those with (62.5% vs 55.3% at 12 months, log-
rank p=0.25) (Supplementary Figure 1). We observed a significant drop in faecal calprotectin 
levels after 3, 6 and 12 months of treatment compared to baseline (Figure 2). 
Cumulative rates of resectional surgery were 5.4% and 13.1% after 6 and 12 months of 
vedolizumab respectively (pan-proctocolectomy with ileostomy n=10; subtotal colectomy 
n=1; ileocaecal resection n=8; ileocaecal resection for stricturing disease n=2; ileocaecal 
resection for penetrating disease n=3; ileocaecal resection for perforation n=2). Surgical 
procedures for perianal disease were performed in 11 patients (fistulotomy n=1; fistulectomy 
n=2; examination under anaesthesia with drainage of abscess and seton insertion n=8). 
3.4 Predictors of treatment outcomes in Crohn’s disease
Multivariable Cox regression analysis revealed individuals with an IBD related 
hospitalisation in the last 12 months were less likely to achieve clinical remission (HR 0.59, 
0.40-0.86, p<0.01) (Table 3). However, no predictive factors were identified for achieving 
mucosal healing or deep remission (Table 3). Stratifying patients by prior IBD admissions 
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revealed significantly higher cumulative rates of clinical remission in those that had not been 
hospitalised due to their IBD in the 12 months prior to vedolizumab (65.3% vs 49.1% at 12 
months, log-rank p<0.01). However, no difference was seen in cumulative mucosal healing 
(61.6% vs 34.3% at 12 months, log-rank p=0.03), deep remission (58.4% vs 20.0% at 12 
months, log-rank p=0.003) or resectional surgery. Comparison of baseline disease activity 
measures showed no difference in median HBI (7 vs 6, p=0.07) (HBI available in n=130) 
and FC levels (540 vs 780 µg/g, p=0.30) (FC available in n=130) but did show higher CRP 
levels (7.5 vs 7.0 mg/L, p=0.02) (CRP available in n=256) between patients with previous 
IBD related hospitalisations versus those without.
Stratifying patients by previous TNF exposure revealed no significant difference for 
cumulative clinical remission (61.3% vs 57.8% at 12 months, log-rank p=0.27), mucosal 
healing (37.0% vs 39.4% at 12 months, log-rank p=0.92), deep remission (27.3% vs 28.5% 
at 12 months, log-rank p=0.91) and resectional surgery (3.0% vs 14.6% at 12 months, log-
rank p=0.13) between patients who were anti-TNF naïve and exposed (Supplementary 
Figure 3).
3.4 Safety
The combined CD and UC cohort had over 333 patient years of follow-up (PYF). Dose 
escalation to Q4 vedolizumab was carried out in 9 UC patients (after 3 months due to sub-
optimal response) and 6 CD patients (after 6 months due to loss of response [n=3] and sub-
optimal response [n=3]). The rate of serious adverse events was 15.6 per 100 PYF (Table 
2). The rate of serious infections was 6.3 per 100 PYF, however the majority continued 
vedolizumab following treatment of their infection. There was a total of 4 (0.9%) infusion 
reactions and 2 (0.5%) delayed hypersensitivity reactions, all requiring discontinuation of 
vedolizumab. Arthralgia was the most common non-infective severe adverse event (3.3 per 
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100 PYF). No deaths occurred during follow-up. Three malignancies were reported during 
treatment. One patient was diagnosed with a cholangiocarcinoma following 4 doses of 
vedolizumab. However, he was thought to also have concurrent PSC. Another patient was 
diagnosed with metastatic ovarian cancer after 3 doses of vedolizumab. The final patient 
underwent a colectomy due to non-response to vedolizumab and upon review of his 
pathology was found to also have a colonic neuro-endocrine tumour. In patients undergoing 
surgery following vedolizumab, post-operative complications (30-day) were observed in 
22.2% (Clavien Dindo Grade 1: n=2; Grade 2: n=2) and 19.2% (Clavien Dindo Grade 1: n=1; 
Grade 2: n=2; Grade 3: n=2) of the UC and CD patients respectively.
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Here we present results from a large, multi-centre, real-world cohort investigating the 
effectiveness and safety of vedolizumab in the treatment of patients with IBD. To our 
knowledge, this is the largest UK cohort published to date, with data not only on clinical 
outcomes but also assessment of mucosal healing. In our cohort, we observed 12-month 
cumulative clinical remission, mucosal healing and deep remission rates of 57.4%, 47.3%, 
38.5% in UC respectively; and 58.4%, 38.9%, 28.3% in CD respectively. We were also able 
to show a significant drop in FC for both CD and UC after 3-months of treatment. 
Furthermore, with over 333 patient years of follow-up no new safety signals were observed. 
These results are in keeping with other previously reported experiences and add to the 
growing body of literature on the effectiveness and safety of vedolizumab in the real world. 
Our results support the use and effectiven ss of vedolizumab for the treatment of both UC 
and CD. Despite both cohorts being mature with high anti-TNF exposure (61.7% in UC; 
88.5% in CD) by 12-months over 50% of patients were able to achieve clinical remission. 
Adopting a NRI analysis, clinical remission rates of 19.4% and 16.2%; and mucosal healing 
rates of 15.8% and 9.3% were observed in UC and CD at 12 months respectively. However, 
these estimates are conservative and several patients who had missing data at 12 months 
or had less than 12 months follow up, had already achieved the end point of clinical 
remission and/or mucosal healing. Furthermore, we did observe in both cohorts that FC 
dropped significantly by 3-months (Figure 2). When assessing cumulative mucosal healing, 
superior rates were observed in UC, possibly due to the greater number of anti-TNF naive 
patients (Table 1). For both cohorts, the greatest benefit was observed after >6 months of 
treatment. This observation has been reported by others and suggests that in many patients 
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vedolizumab may have a slower onset of action and persistence to >6 months of therapy is 
required to achieve optimum outcomes.12-15 
In UC, our results are in keeping with other real-world cohorts from the US (12-month 
cumulative clinical remission, 51.0%; 12-month cumulative endoscopic remission, 41.0%; 
NRI 12-month clinical remission, 20.0%; NRI 12-month mucosal healing, 17.0%), France 
(12-month clinical remission, 42.1%), Sweden (12-month clinical remission, 64.0%), Canada 
(12-month: clinical remission 62.0%; endoscopic remission 47.8%) and Germany (NRI 12-
month clinical remission, 25.0%).13-18 Again in CD our results are similar to those reported 
by others, although there appears to be more variation in published outcomes.11,13-18 For 
example, in the US VICTORY consortium (n=221) which was analysed in a similar way to 
our study, cumulative 12-month clinical remission was 35.0% and mucosal healing much 
higher at 63.0%.14 Their higher mucosal h aling rates compared to clinical remission may 
suggest that a number of the patients had symptoms unrelated to active IBD, especially as 
patients could be included based on symptoms alone.14 Individuals may not always have 
active IBD driving their symptoms (e.g. bile salt malabsorption in patient with small bowel 
resection, irritable bowel syndrome) or have disproportionate symptoms for the degree of 
mucosal inflammation. As such, treatments aimed at treating inflammation may show poor 
efficacy for achieving clinical remission but superior mucosal healing as baseline 
inflammation is not as severe as expected. In contrast to this our inclusion criteria 
necessitated objective evidence of inflammation (HBI ≥5 or Partial Mayo score ≥2 plus CRP 
≥5 mg/L and/or endoscopic / radiographic assessment and/or FC ≥250 µg/g) which might 
explain some of the differences observed. Other reasons for differences in reported 
outcomes between our study and the US VICTORY consortium include; differences in the 
patient populations examined; the use of the PGA to assess efficacy rather than validated 
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disease activity scores; and the definition of mucosal healing necessitating being off 
steroids.14
Optimum positioning of vedolizumab for the treatment of IBD is still unknown and highly 
debated. Currently in the UK, NICE guidelines allow the use of vedolizumab first line in 
patients with moderate to severe UC but in CD stipulate its use only after anti-TNF failure or 
if there are contraindications to anti-TNF use.19,20 Results from the GEMINI trials indicated 
higher efficacy in bio-naive patients for both UC and CD, something that has been echoed 
in other real-world cohorts.7-9,11 In the VICTORY consortium study they showed that previous 
anti-TNF exposure was associated with a reduced probability of achieving clinical remission 
(HR 0.53 [95% CI 0.38-0.75] for UC; HR 0.40 [95% CI 0.20-0.81] for CD)  and mucosal 
healing (HR 0.51 [95% CI 0.29-0.88] for UC; HR 0.29 [95% CI 0.12-0.73] for CD).13,14 We 
observed similar results in patients with UC, where Cox regression analysis identified first 
line use of vedolizumab as the only independent predictor of clinical remission (HR 1.9, 95% 
CI 1.24-2.91, p<0.01), mucosal healing (HR 2.32, 95% CI 1.11-4.89, p=0.03) and deep 
remission (HR 3.78, 95% CI 1.55-9.22, p<0.01) (Table 2). Although, anti-TNF exposed 
patients had a higher baseline FC; partial Mayo scores and CRP were similar between the 
two groups. Furthermore, the proportion of patients on concomitant steroids was higher in 
the anti-TNF naïve group suggesting significant disease. Interestingly, in a recent network 
meta-analysis of randomised controlled trials published by Singh et al., vedolizumab and 
infliximab were ranked highest as first line agents for induction of remission and mucosal 
healing in patients with moderate to severe UC.21 No difference was observed in our CD 
cohort but our analysis was likely underpowered due to the small number of bio-naive 
patients (Supplementary Figure 2). Despite data showing superior efficacy with first line use 
for both CD and UC, in the absence of head to head trials no definite conclusions can be 
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made as to its positioning compared to anti-TNF therapy. However, factors such as safety 
and cost, especially in the advent of biosimilar anti-TNF agents, may also influence health 
trusts and providers.
In our CD cohort, we were unable to identify any independent predictors of mucosal healing 
or deep remission (Table 3). However, we did find that in patients who had an IBD related 
hospitalisation in the prior 12 months to vedolizumab, there was a significantly lower 
probability of achieving clinical remission (HR 0.59, 0.40-0.86, p<0.01) (Table 3). This 
observation may be due to more severe disease in those with prior hospitalisation. Other 
studies have also identified severe disease, active perianal disease and smoking history as 
independent predictors of clinical remission in CD.14 
The mechanism of action of vedolizumab theoretically results in reduced systemic 
immunosuppression and thus superior safety profile when compared to other agents like 
anti-TNF or azathioprine.6 Recently, Colombel et al. published safety data from six 
vedolizumab trials including 2830 patients with over 4800 patient years of follow up.22 
Authors found no increased risk of any infection or serious infection with vedolizumab 
exposure compared to placebo.22 Furthermore, infusion reactions were described in ≤5% of 
patients and reported malignancy rates of <1%, in keeping with background risk.22 In our 
cohort, rates of SAEs were low (15.6 per 100 PYF) and in keeping with the published 
literature. Infusion reactions were also uncommon and no deaths occurred during follow up. 
Three malignancies were reported but these all occurred soon after therapy was initiated 
and thought to be unrelated to vedolizumab.
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There are several strengths to our study. Firstly, we present results from the largest CD and 
second largest UC cohort published to date with data gathered from multiple centres within 
different NHS health boards in Scotland. This allows representation of a diverse patient 
population, capturing practices from both tertiary referral centres and district general 
hospitals treating patients with IBD. In contrast to others, we have also used standardised 
and validated disease activity scores to assess clinical remission. Furthermore, in the 
paradigm shift of treating to normalisation of FC and mucosal healing, we present data on 
the ability of vedolizumab to achieve these important objective end points. However, we also 
acknowledge certain limitations within our study. The retrospective nature of patient 
identification and data collection may have influenced our results. We have tried to 
overcome this by creating a standardised data collection proforma and using objective 
outcome measures where possible. Furthermore, variability in follow-up intervals and both 
assessment and reporting of mucosal healing may have introduced bias. To account for 
differences in follow-up, Kaplan-Meier analysis was used although our results may have 
been influenced by heavy censoring and / or lack of independence between censoring and 
events. Furthermore, we performed a NRI analysis to provide conservative outcomes 
following the use of vedolizumab. In addition, when we compared cumulative clinical 
remission rates depending on whether patients had a follow up for mucosal healing we found 
that in UC cumulative clinical remission rates were significantly higher in patients who did 
not have endoscopic follow up (Supplementary Figure 1). This suggests a possible selection 
bias for performing endoscopy in more unwell patients, therefore outcomes may be 
underestimated. Finally, as our study was multi-centre, encompassing different types of 
hospitals, we would expect some variations in patient populations and practice patterns. 
Although, as previously stated, our aims were to assess real-world outcomes that are 
generalisable to all practice.
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In conclusion, we have shown in a large, real-world, multi-centre cohort that vedolizumab is 
effective at achieving not only clinical remission but mucosal healing at 12-months for both 
UC and CD. In addition, we add to the body of evidence that in UC, first line use results in 
superior outcomes. Finally, our safety data further supports the favourable safety profile of 
vedolizumab in the treatment of IBD. Further real-world prospective as well as head to head 
trials are now required. 
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Table 1. Patient demographics and disease characteristics of cohort. CD, Crohn’s disease; 





Median age, years (IQR) 39 (29-54) 41 (30-56)
Median disease duration, years (IQR) 9 (5-14) 6 (3-11)





























Perianal disease, n (%) 52 (20.0) -
Extra-intestinal manifestations, n (%) 83 (31.9) 44 (24.4)
IBD hospitalisations in last year, n (%) 106 (40.8) 61 (33.9)
Previous Resectional Surgery, n (%) 108 (41.5) -
Previous anti-TNF exposure, n (%) 226 (86.9) 111 (61.7)













Reason for vedolizumab, n (%)
-Failure of IFX and/or ADA
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Concomitant immunosuppressant, n (%) 77 (13.0) 58 (32.2)
Concomitant steroids, n (%) 100 (38.5) 91 (50.6)
Median Harvey-Bradshaw Index, (IQR)* 6 (5-10) -
Median Partial Mayo Score, (IQR)** - 6 (3-8)
Median CRP, mg/L (IQR) 7 (4-15) 5 (2-10)**
Median Faecal Calprotectin*, µg/g (IQR) 690 (250-1065)* 840 (500-1500)**
*Harvey Bradshaw Index, CRP and faecal calprotectin available in n= 130, 256 and 130 at baseline respectively
**Partial Mayo Score, CRP and faecal calprotectin available in n= 120, 164 and 116 at baseline respectively
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Table 2. Univariable and multivariable predictors of outcomes in ulcerative colitis. HR, 
hazard ration; CI, confidence interval
Univariable analyses Multivariable analyses
HR 95% CI p-value HR 95% CI p-value
Clinical Remission
First line treatment 1.99 1.30-3.04 <0.01 1.90 1.24-2.91 <0.01
Age >60 years 0.51 0.27-1.00 0.04
Mucosal Healing
First line treatment 2.19 1.05-4.59 0.04 2.32 1.11-4.89 0.03
IBD related hospitalisation in 
the prior 12 months
0.51 0.21-1.27 0.15
Deep Remission
First line treatment 3.52 1.45-8.58 <0.01 3.78 1.55-9.22 <0.01
Female 0.46 0.17-1.24 0.12
Age >60 years 1.96 0.77-4.98 0.16
IBD related hospitalisation in 
the prior 12 months
0.42 0.14-1.23 0.11
Left sided disease (E2) 0.41 0.11-1.54 0.18
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Table 3. Univariable and multivariable predictors of outcomes in Crohn’s disease. HR, 
hazard ration; CI, confidence interval
Univariable analyses Multivariable analyses
HR 95% CI p-value HR 95% CI p-value
Clinical Remission
Female 0.73 0.51-1.05 0.09
Age >60 years 1.39 0.90-2.14 0.14
IBD related hospitalisation in 
the prior 12 months
0.60 0.41-0.88 <0.01 0.59 0.40-0.86 <0.01
Disease duration >5 years 0.74 0.49-1.12 0.15
Smoking 0.57 0.27-1.23 0.15
Ileo-colonic disease (L3) 1.76 1.03-2.99 0.04
Mucosal Healing
Age >60 years 2.01 0.95-4.26 0.07
Disease duration >5 years 2.54 0.77-8.36 0.12
Penetrating disease (B3) 0.44 0.16-1.26 0.13
Deep Remission
Age >60 years 1.83 0.80-4.21 0.16
Concomitant steroids 1.96 0.90-4.27 0.09
Penetrating disease (B3) 0.31 0.07-1.30 0.11
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Table 4. Cumulative rates of clinical remission, mucosal healing and deep remission 
stratified by (A) previous TNF exposure in ulcerative colitis (B) IBD related hospitalisations 
in the 12 months prior to vedolizumab in Crohn’s disease. 
A.
Overall anti-TNF naive anti-TNF exposed
3M 6M 12M 3M 6M 12M 3M 6M 12M
Clinical Remission 20.0% 43.3% 57.4% 23.8% 53.1% 71.4% 17.6% 29.7% 48.0%
Mucosal Healing 4.2% 17.9% 47.3% 8.6% 20.9% 61.6% 1.6% 11.8% 34.3%
Deep Remission 4.2% 14.3% 38.5% 8.6% 20.9% 58.4% 1.6% 8.0% 20.0%
B.
Overall Hospitalised Not Hospitalised
3M 6M 12M 3M 6M 12M 3M 6M 12M
Clinical Remission 21.9% 39.9% 58.4% 13.7% 28.0% 49.1% 27.4% 40.3% 65.3%
Mucosal Healing 2.3% 10.1% 38.9% 0% 4.4% 31.1% 4.0% 12.6% 43.0%
Deep Remission 1.5% 7.4% 28.3% 0% 4.2% 27.6% 2.6% 9.7% 28.6%
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Table 5. Serious adverse events. PYF, patient years of follow-up.


























6.3 per 100 PYF
Arthralgia 11 (2.5) 3.3 per 100 PYF
Infusion reaction 4 (1.0) 1.2 per 100 PYF
Deranged LFTs 4 (1.0) 1.2 per 100 PYF
Delayed Hypersensitivity 2 (0.4) 0.6 per 100 PYF
Malignancy 3 (0.7) 0.9 per 100 PYF
Bowel Perforation 2 (0.4) 0.6 per 100 PYF
Headache 3 (0.7) 0.9 per 100 PYF
Depression 1 (0.2) 0.3 per 100 PYF
Neutropenia 1 (0.2) 0.3 per 100 PYF
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Figure 1. Study flowchart of patients included in analysis. IBD, inflammatory bowel 
disease; UC, ulcerative colitis; CD, Crohn’s disease.
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Figure 2. Effect of vedolizumab on faecal calprotectin after 3, 6 and 12 months of therapy 
in (A) ulcerative colitis and (B) Crohn’s disease (faecal calprotectin value used if within +/- 
1 month of specified time interval). Dotted line indicates faecal calprotectin cut-off of 250 
µg/g.
Page 34 of 39
https://mc.manuscriptcentral.com/ecco-jcc































































Figure 3. Kaplan-Meier curves for ulcerative colitis treatment outcomes stratified by 
previous anti-TNF exposure. A, cumulative rates of clinical remission; B, cumulative rates 
of mucosal healing; C, cumulative rates of deep remission; D, cumulative rates of 
colectomy. 
Page 35 of 39
https://mc.manuscriptcentral.com/ecco-jcc































































Figure 4. Kaplan-Meier curves for Crohn’s disease treatment outcomes stratified by IBD 
related hospitalisations in the 12 months prior to vedolizumab. A, cumulative rates of 
clinical remission; B, cumulative rates of mucosal healing; C, cumulative rates of deep 
remission; D, cumulative rates of surgery. 
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Supplementary Table 1. (A) Covariates selected for Cox regression model in UC. (B) 
Covariates selected for Cox regression model in CD. 
A.
1 First line treatment
2 Female
3 Age >60 years
4 Disease duration >5 years
5 Disease extent (E1, E2, E3; reference E1)
6 Concomitant steroids
7 Concomitant immunosuppressant
8 IBD related hospitalisation in the prior 12 months
Smoking was not included as a covariate as there were only n=7 documented active 
smokers in the UC cohort.
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1 First line treatment
2 Female
3 Age >60 years
4 Disease duration >5 years
5 Disease distribution (L1, L2, L3; reference L1)
6 Concomitant steroids
7 Concomitant immunomodulator
8 IBD related hospitalisation in the prior 12 months
9 Peri-anal disease
10 Week 10 dose
11 Previous surgery
12 Smoking
13 Penetrating disease (B3)
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Supplementary Figure 1. Cumulative clinical remission rates in UC (A) and CD (B).  
depending on whether endoscopic / MRI follow up was available. MA, mucosal 
assessment. 
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Supplementary Figure 2. Kaplan-Meier curves for Crohn’s disease treatment outcomes 
stratified by previous anti-TNF exposure. A, cumulative rates of clinical remission; B, 
cumulative rates of mucosal healing; C, cumulative rates of deep remission; D, cumulative 
rates of surgery. 
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